Optimizing Drug Development in a Resource Constrained Environment
Life science companies are challenged by the need to streamline their research and development operations in a resource constrained environment. A well informed decision making process is critical to establishing an affordable and trustworthy infrastructure to enable your organization to efficiently nominate and move forward drug candidates.
The BayBio Drug Development Series, a new half-day educational program, will feature case studies from Northern California life science companies, interactive panel discussions focused on best practices, and provide opportunities to network with industry peers.
A small focused exhibit area will offer significant savings of time and effort by providing direct access to dozens of companies specialized in providing the scientific external resources required to support a virtual and semi virtual companies from conception through commercialization.
|9:00AM – 9:15AM||Keynote: Drug Development Success Story
Steven R. Deitcher, M.D.
|9:15AM – 10:30AM||Session 1: Optimizing Drug Development in a Resource Constrained Environment
This dynamic panel will review exceptional drug development success stories in 2012. Chief Medical Officers will share their stories from clinical development challenges, regulatory hurdles, outsourcing strategies and lessons learned to illustrate how they succeeded with often limited resources. This panel will also share clinical design outsourcing models and best practice strategies to help optimize your drug development programs.
Anne-Marie Duliege, M.D., M.S.
Lori Lehman, Ph.D.
Barbara Klencke, M.D.
Gisela Schwab, M.D.
Steven R. Deitcher, M.D.
Lynn Seely, M.D.
|10:30AM – 11:15AM||Networking and Refreshment Break in Exhibit Area|
|11:15AM – 12:15PM||Session 2: Managing Complex Outsourcing Collaborations with Partners and CROs
Relationships will CROs have emerged as a critical factor for the continued and succesful growth of the life science industry. Managing these complex relationships continues to be a challenge for many companies. This session will focus on how strategic partnerships can deliver value beyond traditional transactional models and review key success factors including metrics, governance and transaction vs. collaboration.
Oren Beske, PhD
Lori Kunkel, MD
|12:15PM – 12:30PM||Closing Remarks|
|12:30PM – 1:30PM||Networking Lunch|
Aragen Bioscience, Inc.
Bend Research Inc.
Fujifilm Diosynth Biotechnologies
GVK Biosciences Ltd.
Irvine Pharmaceutical Services, Inc.
|Pharmatek Laboratories, Inc.
Pharsight – A Certara™ Company
Ricerca Biosciences LLC
Schulman Associates IRB
Optimizing Drug Development
March 27, 2013
Gilead Sciences, Inc.
This event is open to qualified life science
|Click Here to Register|
|View Sponsorship Opportunities|
|Attire:||Business Attire Suggested|
- Pre-registered attendees will receive a receipt/confirmation within 24 hours of registration.
- Please print your receipt/confirmation and bring it with you to receive your conference credentials.
- Photo ID (driver’s license or passport) will be required at check-in.
- All sales are final – BayBio offers no refunds.
Please contact Amanda Detzel at firstname.lastname@example.org or
650-871-3257 for further event information and registration.
Sponsorship inquiries, please contact Misha Tsirulnikov at
email@example.com or 650-871-3255.
Is your company a member? Click here to check.
See how your company can save money by becoming a BayBio member!